What is TIVA? Total Intravenous Anaesthesia Explained

TIVA is a method of inducing and maintaining general anaesthesia entirely through intravenous drugs, without using inhaled anaesthetic gases

What is TIVA?

TIVA is a technique used to induce and maintain general anaesthesia entirely through intravenous drugs, without the use of inhaled anaesthetic gases. It most commonly involves a combination of propofol and remifentanil delivered via syringe pumps and is used across a wide range of surgical specialties.

In the UK and Ireland, general anaesthesia is typically induced using an intravenous bolus of anaesthetic drugs and then maintained with inhaled anaesthetic agents.1 TIVA differs from this conventional approach by maintaining anaesthesia solely through intravenous drug administration throughout the procedure.

Current data suggest that approximately 26% of general anaesthetic cases are maintained using TIVA.2

TIVA VS general anaesthetic

TIVAGA
Equipment neededInfusion pumps, syringe drivers
+ IV access
Anaesthetic machine, vaporiser, breathing circuit
Environmental ImpactMinimal atmospheric pollutionVolatile gases contribute to greenhouse emissions
Common AgentsPropofol, remifentanil, ketamine, Dexmedetomidine + muscle relaxantsSevoflurane, desflurane, isoflurane + IV induction
RouteIntravenous infusionVapour inhalation via anaesthetic machine
Post-operative Nausea &
Vomiting (PONV)
Lower incidenceHigher incidence

What are the benefits of TIVA?

Enhanced Patient Recovery and Experience

One of the most widely recognised benefits of TIVA is its ability to reduce the incidence of PONV. Affecting up to 27% of surgical patients, PONV can significantly impact patient comfort, delay recovery, and contribute to substantial additional healthcare costs.3

Evidence suggests that TIVA can help lower this risk compared to inhalational anaesthesia. A review of 229 randomised controlled trials involving 20,991 patients found that those receiving TIVA experienced lower rates of PONV than patients whose anaesthesia was maintained using inhaled anaesthetic agents.4

The benefits of TIVA may extend beyond reducing nausea and vomiting. A 2015 study involving 80 women undergoing thyroid surgery compared recovery outcomes between patients receiving TIVA and those whose anaesthesia was maintained using desflurane with remifentanil infusion. Patients in the TIVA group demonstrated significantly improved recovery outcomes, suggesting a more favourable post-operative experience.5  

Reduced time in Post-Operative Anaesthesia Care Unit

With UK hospitals aiming for around 75% of elective procedures to be performed as day cases, efficient post-operative recovery is an increasingly important consideration.6 As surgical waiting lists continue to place pressure on healthcare systems, reducing recovery times can help improve patient flow, increase bed availability, and support the treatment of more patients.

TIVA has been shown to reduce the time patients spend in the post-anaesthesia care unit (PACU), enabling a faster recovery following surgery. This may be linked to its lower incidence of post-operative nausea and vomiting (PONV) and favourable recovery profile compared to inhalational anaesthesia. As a result, patients may be able to progress more quickly through the recovery pathway and achieve discharge criteria sooner.

In addition, the reduced post-operative discomfort often associated with TIVA may lessen the need for extended monitoring in some patient groups, supporting day-case pathways and helping hospitals work towards their efficiency and discharge targets. By facilitating earlier recovery and discharge, TIVA may contribute to more effective use of healthcare resources while maintaining a positive patient experience.

Post-operative Pain Management

Effective post-operative pain management plays an important role in patient recovery, influencing mobilisation, comfort, and overall satisfaction following surgery. There is evidence to suggest that TIVA using propofol may provide improved acute post-operative analgesia compared with inhalational anaesthesia, potentially reducing pain in the immediate post-operative period.7

However, the extent of this benefit can vary depending on several factors, including the type of surgical procedure performed and the anaesthetic and analgesic techniques used alongside TIVA.7 While further research is needed to fully understand the relationship between TIVA and post-operative pain control, current evidence indicates that propofol-based TIVA may contribute to a more comfortable recovery for some patients.

Mediplus Dedicated TIVA Sets are meticulously designed in collaboration with anaesthetists to meet the highest standards as outlined by the SIVA, Euro SIVA, and AAGBI guidelines.

FAQs

Which drugs can be used in TIVA?

TIVA can be performed using a combination of drugs, with the most utilised groups of drugs including hypnotics and short-acting opioids.   

Two of the most common drugs are remifentanil and propofol. Propofol has revolutionised IV anaesthesia since it became widely available in the mid-1980s. Usually, there is a relatively rapid and clear-headed recovery it provides patients.1 For this article, the discussion of TIVA will refer mostly to anaesthesia induced and maintained through intravenous infusion. 

In which specialties can TIVA be used?   

TIVA can be used for many surgical procedures that require anaesthesia, see below. It is particularly useful when reducing PONV or preserving neurophysiological monitoring is important. However, volatile anaesthesia may still be preferred in some situations, such as severe bronchospasm.

The importance of the perioperative period in cancer metastasis is known, which is why it is important to consider all aspects of surgery when looking at how to improve survival rates, including anaesthesia.   

A study comparing the use of volatile anaesthetics and TIVA in oesophageal cancer surgery found that although there was no difference in the cancer recurrence rate between the two, patients who underwent TIVA had a better survival rate.   

In the entire cohort, the overall mortality rate during follow-up was 41.4% (382/922) in all patients, 51.3% (98/191) in the VA group, and 36.4% (284/731) in the TIVA group.8

TIVA doesn’t rely on normal pulmonary function to administer active agents. This means that it is well-suited to procedures on the upper airway, allowing for tubeless thoracic surgery. 

When compared with general anaesthetic, it has been suggested that TIVA may improve surgical field quality, reduce blood loss and decrease operative time for endoscopic sinus surgery.9

TIVA agents like propofol and remifentanil offer many desirable characteristics that cardiac patients may benefit from, such as improved organ perfusion and protection, modulation of inflammation and brain protection.   

TIVA may be recommended for cardiac surgery as when combined with comprehensive target-controlled drug delivery systems that can be adjusted to the specifics of cardiopulmonary bypass, it can be titrated safely and effectively in delicate and sick cardiac patients.10   

The main function of anaesthesia in neurosurgery is to provide the patient with stable hemodynamics and reduced cerebral metabolism. Anaesthesia also needs to avoid intracranial hypertension and interfering with intraoperative neuromonitoring. It should also allow for rapid emergence from anaesthesia for neurological examination.11 

Volatile anaesthetics (VA) have been shown to affect cerebral autoregulation12 and intracranial pressure13 which may mean that neurosurgery using VA have higher risks such as ischemic cerebral insults.11 

Regarding hemodynamic stability, emergence times, extubation times, early cognitive function, and adverse events, TIVA is similar to volatile anaesthetics. However, several prospective, randomised trials suggest that increased intracranial pressure can be decreased while cerebral perfusion can increase in patients who received TIVA during craniotomy procedures.14  

Robot-assisted Laparoscopic Radical Prostatectomy (RLRP) usually requires a steep Trendelenburg position and prolonged intraperitoneal carbon dioxide insufflation which results in increased intrabdominal pressure. This is known to cause peritoneal stretching and irritation, which can result in PONV.15

Anaesthesiologists should take additional steps to prevent PONV during RLRPs due to the increased risk of developing it. As mentioned previously, preventing PONV is important for both patients and hospitals. 

TIVA has been shown to reduce PONV, with one study investigating its effects in patients undergoing RLRP. In the prospective single-site, double-blinded, randomized, and parallel-arm controlled trial, 62 patients were randomly assigned to the DES or TIVA group. The incidence of nausea in the post-anaesthetic care unit was 22.6% in the DES group and 6.5% in the TIVA (p=0.001) group. The post-operative incidence of nausea at 1-6 hours was 54.8% in the DES group and 16.1% in the TIVA group (p=0.001).15 

Obese patients are at increased risk of respiratory complications and postoperative nausea and vomiting (PONV); therefore, the use of TIVA can provide faster and clearer recovery, reduce nausea, and improve respiratory control through the use of short-acting agents, particularly in patients with obstructive sleep apnoea.

In day-case surgery, TIVA supports rapid recovery and early discharge by minimising nausea, reducing postoperative grogginess, and improving overall patient satisfaction.

In orthopaedic surgery, TIVA fits well with enhanced recovery pathways by facilitating early mobilisation, reducing opioid requirements when combined with regional anaesthesia, and preserving neurophysiological monitoring during spinal procedures.

What are the environmental benefits?

Reducing healthcare-related emissions is becoming an increasingly important priority as hospitals and healthcare systems work towards their sustainability goals. In the United States alone, healthcare is estimated to account for up to 10% of national greenhouse gas emissions.⁵ In the UK, NHS England has committed to achieving net zero carbon emissions by 2050 while continuing to deliver high standards of patient care.

A significant contributor to anaesthesia-related emissions is the use of volatile anaesthetic agents. All volatile anaesthetics are potent greenhouse gases, with global warming potentials (GWPs) ranging from 440 to 6,810 times that of carbon dioxide, which has a reference value of 1. These gases can remain in the atmosphere for extended periods, contributing to their overall environmental impact. For example, nitrous oxide, which is commonly used in clinical practice, has a GWP of 289 and an atmospheric lifetime of approximately 120 years.

As awareness of these environmental impacts grows, some healthcare organisations have taken steps to reduce the use of high-emission anaesthetic agents. Amsterdam University Medical Centre (UMC), for example, has banned the use of nitrous oxide, desflurane, and isoflurane, resulting in a 70% reduction in annual anaesthetic gas canister consumption.17

Because TIVA maintains anaesthesia using intravenous drugs rather than volatile anaesthetic gases, it avoids the direct greenhouse gas emissions associated with inhalational anaesthesia. As a result, TIVA can support hospitals in reducing the environmental footprint of surgical care while continuing to deliver effective anaesthesia for a wide range of procedures.

Is TIVA safer than general anaesthesia?

TIVA and general anaesthesia are considered equally safe when delivered appropriately by trained anaesthetists with standard monitoring. In some situations, TIVA may offer advantages, such as reduced postoperative nausea and vomiting (PONV), smoother recovery, avoidance of malignant hyperthermia-triggering agents, and improved conditions for neurophysiological monitoring. However, it also carries specific risks, including infusion pump failure, accidental interruption of drug delivery, and a potential risk of awareness if not carefully monitored.

What equipment is needed for TIVA?

TIVA requires reliable intravenous access and the use of syringe drivers or infusion pumps to deliver anaesthetic drugs continuously. Standard anaesthetic monitoring, including ECG, pulse oximetry, capnography, and blood pressure monitoring, is also essential. Airway equipment and oxygen supplies must be immediately available, and depth of anaesthesia monitoring such as BIS is often used to reduce the risk of awareness. In some centres, target-controlled infusion (TCI) pumps are used to allow more precise delivery of intravenous anaesthetic agents.

5 key takeaways about TIVA 

  1. TIVA can use a single drug or a combination of drugs, with the two mains ones being propofol and remifentanil. 
  2. It can be used successfully across a broad range of specialties.   
  3. TIVA is inducing and maintaining anaesthesia solely through intravenous infusion, eliminating the need for inhalation agents. 
  4. As climate action becomes a bigger priority for hospitals, TIVA offers one solution to cutting emissions.   
  5. TIVA can be especially useful in reducing PONV, which could help to move patients to discharge quicker.   

References

  1. NAP5 Report – The National Institute of Academic Anaesthesia. Accessed July 21, 2022. https://www.nationalauditprojects.org.uk/NAP5report 
  2. Kane, Andrew David, et al. “Patient characteristics, anaesthetic workload and techniques in the UK: an analysis from the 7th National Audit Project (NAP7) activity survey.” Anaesthesia 78.6 (2023): 701-711.
  3. Amirshahi M, Behnamfar N, Badakhsh M, et al. Prevalence of postoperative nausea and vomiting: A systematic review and meta-analysis. Saudi J Anaesth. 2020;14(1):48-56. doi:10.4103/sja.SJA_401_19  
  4. Schraag S, Pradelli L, Alsaleh AJO, et al. Propofol vs. inhalational agents to maintain general anaesthesia in ambulatory and in-patient surgery: a systematic review and meta-analysis. BMC Anesthesiology. 2018;18(1):162. doi:10.1186/s12871-018-0632-3 
  5. Lee WK, Kim MS, Kang SW, Kim S, Lee JR. Type of anaesthesia and patient quality of recovery: a randomized trial comparing propofol-remifentanil total i.v. anaesthesia with desflurane anaesthesia. Br J Anaesth. 2015;114(4):663-668. doi:10.1093/bja/aeu405 
  6. Guidelines for day-case surgery 2019 Guidelines from the Association of Anaesthetists and the British Association of Day Surgery C. R. Bailey,1 M. Ahuja,2 K. Bartholomew,3 S. Bew,4 L. Forbes,5 A. Lipp,6 J. Montgomery,7 K. Russon,8 O. Potparic9 and M. Stocker10 1 Consultant, Department of Anaesthesia, Guy’s and St Thomas’ NHS Foundation Trust, London and Chair of Working Party, Association of Anaesthetists 2 Consultant, Department of Anaesthesia, Royal Wolverhampton Hospitals NHS Trust and elected member, British Association of Day Surgery 3 Consultant, Department of Anaesthesia, Calderdale and Huddersfield NHS Foundation Trust and elected member, Association of Paediatric Anaesthetists of Great Britain and Ireland 4 Consultant, Department of Anaesthesia, Leeds Teaching Hospitals NHS Trust and elected member, Association of Paediatric Anaesthetists of Great Britain and Ireland 5 Specialist Registrar, Department of Anaesthesia, Ninewells Hospital, Dundee and elected member, Trainee Committee, Association of Anaesthetists 6 Consultant, Department of Anaesthesia, Norfolk and Norwich University Hospital and elected member, British Association of Day Surgery 7 Consultant, Department of Anaesthesia, Torbay and South Devon NHS Foundation Trust and elected member, British Association of Day Surgery 8 Consultant, Department of Anaesthesia, Rotherham NHS Foundation Trust and elected member, British Association of Day Surgery 9 Associate Specialist, Department of Anaesthesia, Chelsea and Westminster NHS Foundation Trust and SAS Committee, Association of Anaesthetists 10 Consultant, Department of Anaesthesia, Torbay and South Devon NHS Foundation Trust and President, British Association of Day Surgery
  7. Stanley Sau Ching Wong ; Wing Shing Chan ; Michael G. Irwin ; Chi Wai Cheung Total Intravenous Anesthesia (TIVA) With Propofol for Acute Postoperative Pain: A Scoping Review of Randomized Controlled Trials Asian Journal of Anesthesiology ; 58卷3期 (2020 / 09 / 01) , P79 – 93  英文 DOI: 10.6859/aja.202009_58(3).0001  
  8. Jun IJ, Jo JY, Kim JI, et al. Impact of anesthetic agents on overall and recurrence-free survival in patients undergoing esophageal cancer surgery: A retrospective observational study. Sci Rep. 2017;7(1):14020. doi:10.1038/s41598-017-14147-9 
  9. Total intravenous anesthesia vs inhaled anesthetic for intraoperative visualization during endoscopic sinus surgery: a double blind randomized controlled trial Michael Little MD, Victor Tran MD, FRCPC, Angelo Chiarella MD, FRCPC, Erin D. Wright MDCM, MEd, FRCSC First published: 10 September 2018 https://doi.org/10.1002/alr.22129
  10. Schraag S. TIVA for Cardiac Surgery. In: Absalom AR, Mason KP, eds. Total Intravenous Anesthesia and Target Controlled Infusions. Springer International Publishing; 2017:579-588. doi:10.1007/978-3-319-47609-4_30 
  11. Lamperti M, Ashiq F. TCI and TIVA for Neurosurgery: Considerations and Techniques. In: ; 2017:561-569. doi:10.1007/978-3-319-47609-4_28 
  12. Matta BF, Heath KJ, Tipping K, Summors AC. Direct cerebral vasodilatory effects of sevoflurane and isoflurane. Anesthesiology. 1999;91(3):677-680. doi:10.1097/00000542-199909000-00019 
  13. Magni G, Baisi F, La Rosa I, et al. No difference in emergence time and early cognitive function between sevoflurane-fentanyl and propofol-remifentanil in patients undergoing craniotomy for supratentorial intracranial surgery. J Neurosurg Anesthesiol. 2005;17(3):134-138. 
  14. Cole CD, Gottfried ON, Gupta DK, Couldwell WT. Total intravenous anesthesia: advantages for intracranial surgery. Neurosurgery. 2007;61(5 Suppl 2):369-377; discussion 377-378. doi:10.1227/01.neu.0000303996.74526.30 
  15. Yoo YC, Bai SJ, Lee KY, Shin S, Choi EK, Lee JW. Total Intravenous Anesthesia with Propofol Reduces Postoperative Nausea and Vomiting in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy: A Prospective Randomized Trial. Yonsei Med J. 2012;53(6):1197-1202. doi:10.3349/ymj.2012.53.6.1197 
  16. Eckelman MJ, Sherman J. Environmental Impacts of the U.S. Health Care System and Effects on Public Health. PLOS ONE. 2016;11(6):e0157014. doi:10.1371/journal.pone.0157014 
  17. Amsterdam University. Climate change – Is it time to say goodbye to inhaled anesthesia? ScienceBlog.com. Published June 6, 2022. Accessed July 19, 2022. https://scienceblog.com/531126/climate-change-is-it-time-to-say-goodbye-to-inhaled-anesthesia/ 

Thank you

We have received your request. We will be in touch as soon as possible